Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, according to a press release.
The agreement includes Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab, Genentech), and Opuviz (aflibercept-yszy), a biosimilar referencing Eylea (aflibercept, Regeneron), according to the release.
In 2021, Byooviz became the first ophthalmology biosimilar to obtain FDA approval. It is indicated for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion and myopic